SEC Form 4/A · accession 0001213900-19-001091
Inspire Medical Systems, Inc. · INSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Joyce Erony
Director
Period of report
Jan 14, 2019
Accepted (ET)
Jan 23, 2019 · 10:36 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001609550
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F8 | Jan 14, 2019 | S | 88,000 | $48.6866 | D | 1,409,043 | I | See Footnote |
| Common StockF3,F8 | Jan 15, 2019 | S | 2,000 | $48.0269 | D | 1,407,043 | I | See Footnote |
| Common StockF4,F8 | Jan 15, 2019 | S | 90,000 | $48.8176 | D | 1,317,043 | I | See Footnote |
| Common StockF5,F8 | Jan 15, 2019 | S | 22,568 | $49.2684 | D | 1,294,475 | I | See Footnote |
| Common StockF6,F8 | Jan 16, 2019 | S | 30,704 | $50.8255 | D | 1,263,771 | I | See Footnote |
| Common StockF7,F8 | Jan 16, 2019 | S | 67,432 | $50.1336 | D | 1,196,339 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Amzak Health Investors, LLC ("Amzak Health") on December 10, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.515 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $48.37. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.11 to $49.43. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.945 to $49.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.455 to $51.435. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F7The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.23 to $51.26. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F8These shares are held of record by Amzak Health. The reporting person, a director of the Issuer, Michael D. Kazma, and Anders Hove are managers of Amzak Health and, as a result, have shared voting and dispositive power over the shares held by Amzak Health. The reporting person disclaims beneficial ownership of the shares held by Amzak Health except to the extent of her proportionate pecuniary interest therein.
Remarks
This report on Form 4/A amends and replaces in its entirety the Form 4 filed by the reporting person on January 16, 2019. This report on Form 4/A is being filed sole to correct a typographical error in (i) the year of the earliest transaction in Item 3 and (ii) the year of the reportable transactions identified in each line of Table I, Box 2, from 2018 to 2019.